LONDON |
Wed Dec 12, 2012 6:31pm EST
LONDON (Reuters) – There is small justification to behind a use of a cannabis remove mist done by GW Pharmaceuticals for spasticity in patients with mixed sclerosis, according to a medical biography examination published on Thursday.
GW Pharma pronounced a news in a Drug and Therapeutics Bulletin (DTB), a British Medical Journal publication, gave “a dubious perspective of a drug” and contained a series of errors.
Sativex is sole as a medication drug in Britain by GW’s partner, German organisation Bayer.
The under-the-tongue mist was authorized by British regulators in 2010 in a vital boost for GW, that spent some-more than a decade building a product.
The DTB, however, pronounced a justification ancillary a use was deficient to clear slight use. “We trust that such stipulations make it formidable to brand a place of this product in clinical practice,” a examination concluded.
GW Pharma pronounced a essay contradicted a opinion of 22 apart inhabitant authorities in Europe and around a universe that have postulated capitulation for Sativex.
It also remarkable a drug had already been authorized by medical payment authorities in Germany and Spain, a usually dual European countries in that grave assessments as to either it should be paid for have been carried out.
British sales of Sativex totaled 2.4 million pounds ($3.9 million) in a year to Sep 30, out of sum net sales of 10 million pounds, adult from 5.3 million a year earlier. The drug is now sole in Britain, Germany, Spain, Denmark, Norway, Canada and Israel.
($1=0.6210 British pounds)
(Reporting by Ben Hirschler; Editing by Greg Mahlich)
Source: Health Medicine Network